MAFAbrocitinib Tablet 50 mg, 100 mg, 200 mg
Treatment of moderate to severe atopic dermatitis (AD)
Additional clinical criteria
Moderate to severe AD (initial - first 16 weeks of treatment)
The patient on initial application:
• has Physicians Global Assessment (PGA) baseline score of 3 or 4 and has Eczema Area and Severity Index (EASI) baseline score of at least 16 despite treatment with at least 1 systemic therapy, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil for a duration of at least 12 weeks, unless contraindicated or not tolerated; AND
• has Dermatology Life Quality Index (DLQI) baseline score measured before initiation of abrocitinib.
Moderate to severe AD (renewal)
The patient on renewal prescription, has achieved or maintained an adequate response defined as:
• an improvement in the Eczema Area and Severity Index (EASI) score of at least 50% compared to baseline; AND
• an improvement in Dermatology Life Quality Index (DLQI) score of at least 4 points compared to baseline.